Hiteen

Quick links to important sections

Hiteen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hiteen

What is Hiteen?

Hiteen is a topical dermatological treatment formulated as a gel. It is a combination medication used primarily for the management of specific types of acne. The formulation combines two active therapeutic components: erythromycin and isotretinoin.

Mechanism of Action

The effectiveness of Hiteen is derived from the synergistic action of its two main ingredients, which address different factors involved in the development of acne lesions.

  • Erythromycin: This is an antibiotic belonging to the macrolide group. When applied topically, it works by inhibiting the growth of Cutibacterium acnes (formerly known as Propionibacterium acnes), the bacteria commonly associated with acne. It also possesses anti-inflammatory properties that help reduce the redness and swelling of acne spots.
  • Isotretinoin: This is a retinoid, a derivative of Vitamin A. It works by normalizing the growth and shedding of skin cells within the hair follicles. This process helps prevent the formation of comedones (whiteheads and blackheads) by ensuring that pores do not become blocked by dead skin cells and excess sebum.

Clinical Application

Hiteen is typically indicated for the treatment of moderate forms of acne, particularly when both inflammatory lesions (such as papules and pustules) and non-inflammatory lesions (comedones) are present. By targeting both the bacterial colonization and the clogging of pores, the gel aims to improve the overall appearance of the skin and prevent the progression of the condition.

Unlike oral retinoids, this topical application focuses the treatment directly on the affected areas of the skin, minimizing systemic exposure to the active ingredients.

What side effects are possible with Hiteen?

Possible Side Effects and Safety Information

The safety profile of Hiteen is structured around local skin irritation and sensitivity, as documented in authoritative regulatory sources.


Adverse Reactions by System and Frequency

The most commonly reported adverse reactions are local skin reactions at the application site. These effects are often most frequent during the initial two weeks of therapy and then typically decrease in occurrence or severity with continued use. Adverse reactions are grouped by the body system affected:

  • Skin and Subcutaneous Tissue Disorders: Includes reactions such as skin pain, stinging, burning sensation, excessive dryness, peeling (exfoliation), redness (erythema), itching (pruritus), and dermatitis. Blistering and crusting have also been reported.
  • Immune System Disorders: Severe hypersensitivity reactions have been reported in postmarketing experience, including anaphylaxis and angioedema.

Serious Safety Considerations and Limitations

Serious Adverse Reactions

Regulatory documents identify the potential for severe hypersensitivity reactions, such as anaphylaxis, which require immediate discontinuation of the medication.

Safety Restrictions and Context-of-Use Notes

The medicine is contraindicated in individuals with a known hypersensitivity to the drug or any of its components.

Patients using Hiteen must implement sun protection measures, including the use of sunscreen and protective clothing, as the medicine is associated with photosensitivity (increased sensitivity to ultraviolet light). Application must be avoided on skin that is cut, abraded, eczematous, or sunburned, as this may lead to marked irritation. Extreme weather conditions, such as severe wind or cold, may also increase the risk of skin irritation.

Population-Specific Considerations

For females of reproductive potential, there are published case reports of major birth defects in infants exposed to topical tretinoin during the first trimester; however, no pattern of malformations has been established. Caution is noted for use in patients with a history of eczema due to the increased risk of severe local irritation.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory documentation for Hiteen (Erythromycin and Tretinoin) defines overdose scenarios based on two main exposure types: excessive topical application and accidental oral ingestion.

Documented Overdose Manifestations

Exposure Type Manifestation Required Action
Excessive Topical Use Marked redness, severe peeling, or excessive local discomfort. Discontinue use until irritation subsides.
Accidental Oral Ingestion Side effects consistent with excessive oral intake of Vitamin A (Systemic Retinoid Toxicity). Seek immediate medical attention.

Severe Systemic Risks

Overdose or complication involving the Erythromycin component is linked to the potential development of Clostridioides difficile-associated diarrhea (CDAD). This complication may manifest as severe, persistent, or bloody diarrhea or severe stomach cramps. Serious outcomes are documented to include Colitis, Pseudomembranous Colitis, Toxic Megacolon, or Perforation of the Colon.

Immediate Emergency Response

In all cases of suspected overdose or accidental oral ingestion, regulatory instructions mandate contacting a Poison Control Center or Emergency Room at once. Immediate medical help is also required if severe diarrhea is observed. Management of severe complications often involves supportive measures such as fluids and electrolytes, protein supplementation, and potentially hospital monitoring or surgical evaluation. No specific antidote for the active ingredients is documented in the official regulatory information.

Therapeutic Uses of Hiteen

What Hiteen Treats: Main Uses and Benefits

Hiteen is commonly used to manage mild to moderate acne vulgaris by addressing the core symptomatic patterns that define the condition. The combination therapy is relevant when symptoms interfere with daily comfort.


Clearing Non-Inflammatory Lesions and Clogged Pores

This medication is considered relevant for conditions marked by the formation of non-inflammatory lesions, which include blackheads (open comedones) and whiteheads (closed comedones). This treatment may assist with the management of these follicular obstructions, which may be part of symptomatic management used to support functional stability and may assist with managing the risk of progression into more pronounced manifestations.


Support for Inflammatory Symptoms

Hiteen is commonly used to help with the group of symptoms associated with active breakouts, specifically red, raised papules and pus-filled pustules. This dual focus supports the management of distressing symptoms. By supporting the management of these visible and painful manifestations, the therapy contributes to easing discomfort during symptomatic periods.


Support for Recurrent and Episodic Manifestations

The combination topical agent is commonly used across conditions presenting with episodic symptoms generally associated with moderate acne vulgaris, and is generally applied as a foundational approach when appropriate. It is applied across chronic management scenarios where the symptoms require sustained assistance in stabilization, offering supportive relief that helps patients cope with symptom fluctuations.


Quick Fact: Relief for Polymorphic Acne
Primary Indication: Mild to moderate acne vulgaris
Symptom Coverage: Non-inflammatory comedones and inflammatory papules/pustules
Typical Context: Chronic management to support long-term stability

Regulatory References

  1. Canada.ca (Health Canada) on Acne Treatments

Eligibility and Restrictions for Use

The official regulatory profile for this medication, based on authoritative government drug labels, defines strict eligibility criteria and contraindications for use.

Eligibility Restrictions (Contraindications and Limitations)

Classification Restricted Populations or Conditions
Absolute Contraindication Patients with known hypersensitivity to any component of the medication, or those with severe or uncontrolled hypertension (high blood pressure). Also prohibited for patients with severe acute or chronic kidney disease (renal failure), and those with narrow-angle glaucoma or urinary retention (e.g., due to prostatic enlargement).
Concurrent Medications Use is contraindicated within 14 days of stopping therapy with a Monoamine Oxidase Inhibitor (MAOI), or with other sympathomimetic agents (e.g., certain decongestants).
Age-Related Rules Use is not recommended or contraindicated in children younger than 6 years of age. Use in older children (6–12 years) may be subject to stricter duration limits.
Reproductive Status Use during pregnancy is not recommended and should be avoided due to regulatory concerns regarding potential fetal exposure, particularly in the first trimester. Caution is recommended during breastfeeding as the medication is excreted into human milk and may potentially interfere with milk supply.

These official eligibility statements strictly define the population for whom the medicine may be safely and legally used, based on established public health and regulatory data. Patients with any of the above conditions are formally excluded from using this medication.

What should I know about interactions with other medicines?

Hiteen Interactions with other medicines and products

Officially documented interaction patterns for this combination topical agent are structured by both local pharmacodynamic effects and potential systemic pharmacokinetic risks. Co-administration with Clindamycin-containing products is restricted due to a documented antimicrobial antagonism involving the Erythromycin component. The regulatory profile also requires specific sequencing: the skin must be allowed to "rest" until the effects of prior topical treatments containing sulfur, resorcinol, or salicylic acid have subsided before beginning the Tretinoin component.

From a pharmacodynamic standpoint, concurrent use with other topical agents known to cause strong drying, irritation, or contain high concentrations of alcohol or astringents may result in a cumulative increase in local skin irritation. The Tretinoin component is also associated with an additive photosensitivity risk when co-administered with other photosensitizing medicines. Metabolically, potent inhibitors of CYP450 2C8 and 3A4 may increase the systemic plasma concentration of Tretinoin. The Erythromycin component is a known inhibitor of CYP3A and may increase the exposure of drugs metabolized by that pathway if systemic absorption occurs. Grapefruit juice has been documented to increase the exposure of the Erythromycin component. Finally, an increased risk of hepatotoxicity is noted for the Tretinoin component in patients with hepatic impairment.

Mechanism of Action

How Hiteen Works


Microbial Protein Synthesis Inhibition

The Erythromycin component acts as an inhibitor by binding reversibly to the 50S subunit of the bacterial ribosome, blocking the nascent peptide exit tunnel. This molecular interaction arrests the synthesis of essential bacterial proteins. This mechanism reduces the local population of certain skin bacteria, directly reducing a pathway that contributes to inflammation and resulting in a reduction of the local microbial population within the skin's structures.


Follicular Cell Differentiation Normalization

The Tretinoin component functions as an agonist of nuclear Retinoic Acid Receptors ( RARs), predominantly RAR-gamma, altering the transcription of genes controlling skin cell growth and adhesion. This action fundamentally modifies the abnormal cohesiveness and accumulation of epithelial cells (hyperkeratinization) within the hair follicle. The resulting physiological change involves the normalization of follicular epithelial structure and the mobilization of follicular cellular material.


Complementary Dual-Factor Modulation

Hiteen employs complementary mechanisms, where the microbial suppression pathway is paired with the cellular normalization pathway. This strategy engages dual targets simultaneously, supporting the co-modulation of microbial load and epithelial structure.

Dosage and Administration Information

Official Administration Instructions

Hiteen (tretinoin) is administered topically, meaning it is applied directly to the skin. This medication should be used strictly according to established clinical protocols, as proper technique is necessary to ensure safe use and to avoid excessive irritation.

Dosing and Application Protocol

Domain Official Instruction
Route & Frequency For topical use only. Apply a thin layer once daily in the evening, or as directed by a healthcare provider.
Preparation Thoroughly cleanse the affected area(s) with a mild, non-medicated cleanser, then gently pat the skin dry. Wait 20 to 30 minutes before applying the medicine to ensure the skin is completely dry.
Quantity Use just enough to very lightly cover the affected area. A pea-sized amount is often considered sufficient to cover the entire face.
Specific Avoidance Areas Keep the medication away from the eyes, mouth, paranasal creases of the nose, and mucous membranes. Do not apply to skin areas that have cuts, scrapes, sunburn, or are otherwise damaged.
Missed Dose If a dose is missed, apply it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed one and return to the regular schedule. Do not double doses.

These official instructions define the required procedural structure: the skin must be cleansed and fully dry before a precise, small amount of the drug is applied to the affected area, once daily at night. Following this protocol, which includes proper pre-application waiting time and site avoidance, is the standard documented method for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hiteen (Erythromycin/Tretinoin Combination)

Evidence for Use in Mild to Moderate Acne Vulgaris

Research explored the patterns observed with the Erythromycin and Tretinoin combination product in individuals with mild to moderate acne vulgaris. Most of the evidence is derived from short-term Randomized Controlled Trials (RCTs) and multicenter double-blind studies. These studies were designed to compare the combination formula against an inactive product (vehicle) or against the two active ingredients used separately (monotherapies). The research explored whether the combination was associated with different outcomes compared to the individual components in the short term.

These short-term trials, typically lasting 10 to 12 weeks, monitored several types of outcomes related to physical discomfort and the visible signs of the condition. Findings describe patterns observed in the studies where the measured changes in total lesion counts appeared to be lower for the combination product group compared to the vehicle group over the 10- to 12-week study duration. The overall results contribute to understanding symptom patterns over these short-defined time intervals.

What Was Studied: Inflammatory and Non-inflammatory Symptoms

The clinical studies research examined two distinct types of acne symptoms: non-inflammatory lesions (like blackheads and whiteheads, known as comedones) and inflammatory lesions (red bumps and pus-filled spots, known as papules and pustules). Non-inflammatory lesions was studied by measuring change in lesion counts, while inflammatory lesions was evaluated by quantifying redness and raised spots. The combination was also observed in studies using an overall rating by a doctor (Investigator's Global Assessment) to provide a high-level description of rated condition status.

Long-term Studies and Durability of Effect

The research exploring the patterns observed with the Erythromycin/Tretinoin combination is generally focused on the short to intermediate term, with the most common observation periods being 10 to 12 weeks. This focus means that there is limited information for long-term outcomes that may extend beyond this initial period. Long-term effects are not fully established regarding sustained use.

Evidence Gaps and Areas for Further Research

A key limitation is that long-term effects are not fully established, as the duration of follow-up in the primary research was limited. Furthermore, comparative evidence is limited for direct comparison with every newer fixed-dose combination product. The research also includes broader scientific considerations related to the topic of microbial resistance, which is a recognized limitation when interpreting evidence for topical antibiotic use.

Frequently Asked Questions (FAQ)

Common questions about Hiteen (FAQ)


Q: What is Hiteen officially approved to treat?

A: According to the official regulatory documents, Hiteen is approved for the topical treatment of Acne Vulgaris. This indication is for patients who are within a specific age range. The product’s purpose is to address both the microbial and cellular factors associated with the skin condition.


Q: Is Hiteen described as suitable for older adults?

A: Official product information may note that studies of Hiteen generally did not include enough patients aged 65 and older to determine if their response is different from that of younger individuals. Because older skin can be more fragile, special precautions related to skin integrity may be outlined in the official warnings.


Q: Where can I find the official regulatory information about Hiteen?

A: When the medication is supplied, it is typically accompanied by an official Patient Information Leaflet or Package Insert. You can also find the full regulatory label and product information on public government health websites, such as the U.S. National Library of Medicine’s DailyMed.


Q: Does Hiteen have a risk of causing dependence or withdrawal symptoms?

A: Regulatory documents, which include the Drug Abuse and Dependence section, typically do not classify Hiteen as having a risk of dependence. Specific withdrawal symptoms are generally not listed for this topical combination agent.


Q: What does the official labeling say about Hiteen and alcohol consumption?

A: Official regulatory warnings for Hiteen focus on avoiding concurrent use of other topical products that contain high concentrations of alcohol or astringents, as this may increase skin irritation. Due to the product's minimal systemic absorption, no specific warnings related to consuming alcoholic beverages are typically noted.


Q: Do regulatory bodies specify any required lab tests while using Hiteen?

A: According to the official regulatory labeling, no routine laboratory tests are specifically required for monitoring patients using this topical medication.


Q: What information is available about Hiteen and driving or operating machinery?

A: Official labeling indicates that Hiteen is not expected to affect a patient's ability to drive or operate machinery. This is based on the product’s design for topical use, which results in minimal absorption into the bloodstream.


Q: Is Hiteen a controlled substance in [Country/Region]?

A: Official drug classification data indicates that Hiteen is a non-scheduled, prescription-only medication. It is not classified as a controlled substance by regulatory agencies.


Q: Is Hiteen known to cause weight changes?

A: Weight change is not typically listed as an adverse reaction in the regulatory documents for this topical combination product. This is because the active ingredients are applied to the skin and have minimal exposure to the rest of the body.


Q: Does Hiteen interfere with birth control pills?

A: Regulatory documents state that Hiteen is not expected to reduce the effectiveness of systemic oral contraceptives (birth control pills). This is due to the minimal absorption of the active ingredients into the bloodstream after topical application.


Q: What does the research suggest about Hiteen and mood changes?

A: Official regulatory reports may note that rare instances of mood changes or disturbances have been reported in the post-marketing experience for retinoid-containing products. However, these reports do not establish a direct cause-and-effect link with Hiteen use.


Q: Is there any official guidance on stopping Hiteen?

A: The official regulatory information indicates that all decisions regarding treatment, including whether to discontinue or interrupt use, are typically made under the guidance of a healthcare provider. There are no official patient instructions for unilaterally stopping the medication.


Q: How is the need for continued use of Hiteen generally assessed by a healthcare professional?

A: Clinical guidance often suggests that the need for continued use is based on the patient’s clinical response. For instance, regulatory documents may note that if no improvement is observed after a defined period, such as 10 to 12 weeks, the medication may be discontinued.


Q: Can Hiteen cause changes in sleep patterns?

A: While official documents do not directly address general sleep patterns, the list of reported side effects may include nervous system adverse reactions. These sometimes include conditions like insomnia (difficulty sleeping) or somnolence (drowsiness).


Q: Is there an official patient leaflet or information sheet for Hiteen?

A: Yes, regulatory requirements mandate that the product is supplied with an official patient information document, such as a Patient Information Leaflet or a Package Insert. These documents are reviewed and approved by health authorities.


Q: Why is Hiteen only available by prescription?

A: Hiteen is classified as a prescription-only medicine because it requires professional medical supervision. This ensures the correct diagnosis is made, potential side effects are managed appropriately, and patients are checked for specific contraindications and safety restrictions listed in the official documents.


Q: How quickly does Hiteen usually start working?

A: Studies referenced in regulatory documents indicate that efficacy is typically evaluated after approximately 8 to 12 weeks of continuous use. It is important to remember that clinical improvement is often gradual, and results are not immediate.


Q: How long does the effect of Hiteen last?

A: Official information suggests that treatment should be continued only as long as benefits are observed. Studies have shown that a decrease in benefits (a return of symptoms) may occur after the medication is discontinued.


Q: Is it normal to feel [mild, common side effect] when first starting Hiteen?

A: Regulatory documents note that local skin reactions like peeling, dryness, and redness are very common with this medication. These reactions are often observed during the initial two weeks of use and may decrease in occurrence or severity with continued application.


Q: What are some common reasons people stop taking Hiteen?

A: Data from clinical trials indicates that the most common reason for participants to stop treatment is the occurrence of local skin adverse reactions. These include sensations such as burning, peeling, and excessive dryness at the application site.


Q: What are the general expectations for someone starting Hiteen?

A: Official patient counseling information describes a set of general expectations when starting this medication. These include the possibility of a temporary worsening of skin appearance during the first few weeks, followed by a gradual reduction in symptoms over the next several weeks of continuous use.


Q: What happens if I take more Hiteen than recommended in the dosage instructions?

A: Regulatory text warns that applying an excessive amount of Hiteen will not result in faster or better results. Instead, it may lead to marked local side effects such as redness, excessive peeling, or discomfort. Significant systemic overdose is not expected due to the medication’s low absorption into the body.


Q: Is Hiteen described as a short-term or long-term medication?

A: Official regulatory guidance indicates that the treatment duration is based on the patient's clinical response. Efficacy trials typically evaluate the medication over a short-to-intermediate period (such as 10 to 12 weeks), and ongoing use is guided by a healthcare professional.


Q: What is the role of Hiteen in a broader treatment plan for its approved use?

A: Regulatory documents describe Hiteen as a fixed-dose combination product that addresses two key underlying causes of the approved condition: microbial growth and abnormal skin cell differentiation. This dual action positions it as a foundational therapeutic approach intended to help normalize the skin structure.


Q: Does Hiteen interfere with common topical products like moisturizer or makeup?

A: The official product instructions often specify a waiting period, noting that Hiteen should be allowed to fully dry on the skin before non-medicated topical products like moisturizers, sunscreens, or makeup are applied. This practice helps ensure the medication is properly absorbed and reduces the risk of mixing the ingredients or increasing irritation.

How should Hiteen be stored and disposed of?

How to Store and Dispose of Hiteen

Hiteen (Erythromycin and Tretinoin topical combination) must be stored and handled according to specific regulatory requirements to maintain its stability and prevent accidental exposure.


Storage Requirements

Hiteen must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from direct light and moisture and must not be frozen.

Due to the components in certain formulations, Hiteen is flammable and must be kept away from heat and open flame.

It is required to keep Hiteen in its original container, ensure the container is tightly closed after use, and store the medicine out of the reach of children.

Disposal Instructions

Unused or expired Hiteen must be disposed of according to local requirements. The medicine should not be flushed down the toilet or poured into a drain. Disposal should utilize a medicine take-back program or involve mixing the product with an undesirable substance (such as dirt) in a sealed plastic bag before being placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hiteen found in:

A-Z Index: